Part D Coverage Could Lead To Drug Price Uniformity, Pfizer Exec Says
Implementation of the Medicare Part D drug benefit could ultimately mean more uniform pricing across different market segments in the U.S., a Pfizer exec suggested Jan. 25
You may also be interested in...
CMS may need to intervene in Medicaid pharmacy reimbursement practices to ensure that the Medicare Part D program runs smoothly, Mintz Levin attorney Carolyn McElroy suggested Feb. 1 during CBI's Pharmaceutical Marketing Compliance Congress in Washington, D.C
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011